Purpose: In a previous phase I trial we evaluated the toxicity and determined the maximum tolerated doses of the docetaxel (D)-epirubicin (Epi) combination. We conducted a multicenter phase II study to evaluate the efficacy and tolerability of this regimen as front-line treatment in women with advanced breast cancer (ABC).
Introduction
At the present time, the anthracyclines and the taxanes are considered to be the most active drugs in advanced breast cancer (ABC). Since the taxanes are also active in anthracycline refractory disease [1] , the combination of an anthracycline with a taxane has the theoretical advantage of overcoming the de novo drug resistance of the tumor, thus leading to improved efficacy and perhaps prolongation of survival. Initial phase I and II studies combined the older drugs from each class, e.g., paclitaxel with doxorubicin and reported a high response rate (up to 90%) but also significant hematologic and non-hematologic toxicity including severe cardiotoxicity in up to 20% of patients [2] [3] [4] [5] .
Epirubicin (Epi) has similar single agent activity with doxorubicin as first-line treatment in metastatic breast cancer (MBC) with response rates of 25%-62% [6] ; however, its toxicity profile is more favorable than doxorubicin especially in terms of cardiotoxicity [6] [7] [8] . Due to its faster elimination leading to a reduced area under the curve than equimolar doses of doxorubicin, Epi can be given at higher doses (120-180 mg/m 2 every three weeks) [9, 10] and with a dose-response curve favoring dose intensification [11, 12] . Docetaxel (D) has impressive single agent activity in MBC with response rates of 54%-68% in previously untreated patients [13] [14] [15] and 41% in patients with anthracycline-resistant disease [16] . Moreover, D is active even in patients with paclitaxel-refractory disease [17] indicating partial non-cross resistance with either doxorubicin or paclitaxel. In randomised studies, D but not paclitaxel was more active than doxorubicin in patients with MBC [18, 19] . Furthermore, D was more active than the combination of mitomycin-vinblastine as salvage treatment in patients with MBC progressing despite previous anthracycline-based chemotherapy [20] . In addition to its high activity, D seems to be less cardiotoxic than paclitaxel [21] .
Based on these data, we performed a dose escalation study with the D and Epi combination in women with ABC [22] . When the combination was administered as front-line treatment, the maximum tolerated doses (MTD) depended on the administration schedule of the drugs with the MTD reached at Epi 60 mg/m 2 and D 80 mg/m 2 when the two drugs were given on the same day and Epi 70 mg/m 2 on day 1 and D 90 mg/m 2 on day 2 when the drugs were given on separate days. The dose limiting events were febrile neutropenia and grade 4 neutropenia with no patient developing congestive heart failure or dying of sepsis. We chose the treatment schedule of two consecutive days which permits administration of higher doses for the two drugs and we conducted a multicenter phase II study to determine the efficacy as well as tolerability of the regimen given as front-line treatment in women with ABC.
Patients and methods

Patient selection
Women aged 18-75 years with histologically confirmed and previously untreated stage 1MB or IV ABC were enrolled. Other eligibility criteria included: the presence of at least one bidimensionally measurable and not previously irradiated lesion, a cumulative doxorubicin dose received at least one year before as part of adjuvant treatment to be less than 300 mg/m 2 or equivalent, a life expectancy of at least three months, performance status (WHO) of 0-2, adequate hematologic parameters (absolute neutrophil count ^ 1500/mm 3 , hemoglobin 5=10 g/dl, platelets > 100,000/mm 3 ), renal (serum creatinine < 1.5 mg/dl) and hepatic (serum bilirubin <1.5 mg/dl, SGPT, SGOT <3 x normal values) function tests. No history of myocardial infarction or unstable angina in the previous six months and normal cardiac function as assessed by MUGA scan or echocardiogram with left ventricular ejection fraction (LVEF) >50%. Patients with brain metastases were allowed to participate provided that they had received cranial irradiation with clinical and radiographic improvement of their CNS disease. Patients with infection, malnutrition or a history of a second malignancy other than basal or squamous-cell carcinoma of the skin or in situ carcinoma of the cervix were not allowed. The study was approved by the Ethics and Scientific Committees of the participating centers and all patients signed a written informed consent to participate in the study.
Treatment
Epirubicin (Farmorubicine; Pharmacia, Milano, Italy) 70 mg/m 2 was administered on day 1 as a 15-minute bolus i.v. infusion and docetaxel (Taxotere; Rhone-Poulenc Rorer; Collegeville, Pennsylvania, USA) 90 mg/m 2 on day 2 as a one-hour i.v. infusion following standard premedication with oral methylprednisolone. Prophylactic antiemetic treatment was given according to investigators' routine practice. Treatment was repeated every three weeks on an outpatient basis for six cycles or until a maximum response was achieved, provided that the total cumulative dose of epirubicin did not exceed 850 mg/m 2 including the equitoxic anthracycline dose received in the adjuvant setting. Patients with disease progression were immediately withdrawn from the study. Epirubicin administration was discontinued in patients developing a LVEF <50% or a 15% decrease of LVEF over pretreatment values or congestive heart failure (CHF). Prophylactic rh-G-CSF was not given with the treatment except for patients developing grade 3-4 neutropenia or febrile neutropenia. Doses of both drugs were reduced by 20% in case of grade 4 neutropenia or febrile neutropenia (despite prophylactic rh-G-CSF) or grade 4 thrombocyto-penia lasting more than five days or > grade 3 non-hematologic toxicity. Post-treatment hormonal or cytotoxic maintenance therapies were not allowed.
Patient evaluation
Baseline evaluation included: patient history, physical examination, chest X-rays, complete blood count with differential (CBC), blood chemistry with CA 15-3 and carcinoembryonic antigen (CEA) measurement, ECG, echocardiography or MUGA scan with LVEF measurement, CTscan of chest and abdomen and a bone scan. CBCs were repeated weekly for all patients throughout the treatment or daily in case of grade 3-4 neutropenia or thrombocytopenia or febrile neutropenia and until hematologic recovery occurred. Before each cycle evaluation included: patient history, physical examination, complete blood count with differential (CBC), blood chemistry with CEA and CA 15-3 determination and an ECG. Other tests were performed when clinically indicated. Cardiac monitoring consisted of physical examination and ECG performed every three weeks and LVEF measurement every three cycles of treatment. Patients developing LVEF < 50% or a 15% decrease of LVEF over pre-treatment values or congestive heart failure were also required to undergo repeat LVEF measurement in three months. Evaluation of response was performed after each cycle if measurable disease was assessable by physical examination or, after every three cycles of treatment by repeating the CT scans. Patients were considered evaluable for response only if they had received at least three cycles of treatment. Toxicity and response to the treatment were scored according to the WHO criteria [23] . Responses were evaluated by an external board of independent radiologists.
Statistical analysis
The duration of response was measured from the first documentation of response until disease progression. Time to progression was determined by the interval between the initiation of therapy to the first date that disease progression was objectively documented. The follow-up time was measured from the day of the first treatment administration to last contact or death. The probability of survival was estimated by the method of Kaplan and Meier [24] , and confidence intervals for response rates were calculated using methods for exact binomial confidence intervals [25] ,
Results
Between January 1998 and April 1999, 54 patients were enrolled. Patient charachteristics are shown in Table 1 .
Median age was 55 years, 49 (91%) patients had PS (WHO) of 0-1, 50 (93%) had metastatic disease and 45 (83%) had visceral involvement. Twenty (37%) patients had previously received adjuvant chemotherapy including eight (15%) patients who had received an anthracyclinebased regimen twelve to one hundred twenty months before this treatment. Fifty patients were evaluable for response. Four patients were not evaluable because of early death due to acute respiratory failure possibly secondary to infection (two patients) and discontinuation of treatment at patient's request due to febrile grade 4 neutropenia after the first cycle (two patients). In an intent-to-treat analysis we observed 5 complete responses (9% CR) and 31 partial responses (57% PR) for an overall response rate of 66% (95% confidence interval: 54%-79%). In addition, nine (17%) patients had stable disease and nine (17%) had progression. The median duration of response was 8 months (range 2-20.5). For patients with visceral involvement the response rate was 74%. Of the eight patients who had previously received anthracycline-based adjuvant therapy, three (37.5%) responded. The response rates for specific disease sites were: locoregional disease 62%, lymph nodes 68%, lungs 69%, liver 83%. Nine (17%) patients received more than six cycles and in three of them there was further improvement in the tumor response with prolonged treatment. After a median follow-up time of 11.5 months (range 1-23), 34 patients are still alive. Eighteen patients have died due to disease progression and two patients due to respiratory failure early during the treatment. The median time to disease progression was 11.5 months (range 3.5-23) and the median overall survival has not yet been reached. The Kaplan-Meier probability of oneyear survival was 65% (Figure 1) .
Three hundred six cycles of treatment were administered with a median of 6 cycles per patient (range 1-10). 
Forty-seven (15%) cycles were delayed due to hematologic toxicity (15 cycles), non-hematologic toxicity (1 cycle) and late patient arrival due to personal reasons or delayed imaging studies for response evaluation (31 cycles). The median interval between all cycles was 21 days (range 21-30); for delayed cycles the median number of days delayed per cycle was 10 (range 5-28). Hematologic and non-hematologic toxicity for all patients and all cycles is shown in In five (9%) patients LVEF decreased by more than 10%. None of the patients developed congestive heart failure or had to stop treatment because of cardiotoxicity. There were two deaths possibly related to the treatment. The first patient (A.K.) was a 63-year-old woman with a parasternal mass relapse who presented 20 days after her third cycle with fever, non-productive cough, severe hypoxia and diffuse patchy infiltrates on the chest X-ray. She was not neutropenic and was initially treated with broad spectrum antibiotics and supplemental oxygen. Due to her progressive respiratory failure, she was intubated and transferred to the intensive care unit where she expired 10 days later with a clinical picture consistent with adult respiratory distress syndrome. No micro-organisms were isolated from blood and sputum cultures. The second patient (M.K.) was a 51-year-old woman with hepatic and bone metastases who developed high fever, dyspnea, hypoxia and bilateral pulmonary infiltrates two days after the second cycle. She was not neutropenic and was treated with oxygen and broad spectrum antibiotics but without any improvement. She died two days later of presumed respiratory sepsis although no micro-organisms were cultured during the initial work-up of her fever. Unfortunately authorization for an autopsy was declined in both cases.
Due to the development of grade 3-4 neutropenia or febrile neutropenia, prophylactic rh-G-CSF was used in 45 (83%) patients or 226 (74%) cycles. In 186 cycles where secondary prophylactic rh-G-CSF was used, grade 3-4 and febrile neutropenia complicated 19 (10%) of 25 (13%) and 11 (6%) cycles, respectively. Dose reduction was performed in 26 (8%) cycles due to hematologic toxicity (16 cycles), non-hematologic toxicity (4 cycles) or abnormal liver function (6 cycles). The median delivered dose intensity was 28 mg/m 2 /week for D and 22 mg/m 2 /week for Epi corresponding to 93% and 94% of the protocol planned doses, respectively.
At the time of the analysis all patients have discontinued treatment for the following reasons: completion of treatment (34 patients), progressive disease (9 patients), toxicity (5 patients), deterioration of PS -patient refused to continue (4 patients), early deaths (2 patients).
Discussion
Several studies have been conducted and more studies are underway investigating the efficacy and toxicity of a taxane-anthracycline combination in early or advanced stages of breast cancer. The rationale for these studies is obvious since a taxane-anthracycline regimen combines the most active drugs for breast cancer which have a different mechanism of action and manifest incomplete cross-resistance. A number of trials have been reported with the paclitaxel plus doxorubicin combination, and the overall response rates have ranged from 48%~94% including 4%-41% complete responses [26] . In these studies hematologic toxicity has been significant but manageable and the most serious adverse effect of the combination has been cardiotoxicity including 6-21% incidence of congestive heart failure [26] . Moreover, the strategy of limiting treatment to a maximum of six cycles in order to reduce the cardiotoxicity, may in fact adversely affect the efficacy of the treatment [26] . Therefore it is not clear which drug combination is the most effective and the least toxic for using in the adjuvant, neoadjuvant or metastatic settings. An alternative approach would be to combine a less cardiotoxic agent from each class e.g. docetaxel and epirubicin, which are known to be equally effective as single agents to paclitaxel and doxorubicin, respectively [6] [7] [8] [13] [14] [15] [16] .
In the present study the combination of D + Epi proved to be very effective in poor-risk women with ABC. The overall response rate was 66% including 9% complete remissions. The regimen was active in patients with visceral involvement, multiple involved sites or reduced performance status. The duration of responses and time to disease progression compare favorably to other regimens [26] . Toxicity was primarily grade 3-4 neutropenia resulting in the prophylactic administration of rh-G-CSF in most patients. Febrile neutropenia complicated less than 10% of the cycles and was always successfully treated with intravenous antibiotics. Severe anemia and thrombocytopenia were very rare. Cardiotoxicity was detected by LVEF measurement in 9% of patients and was never symptomatic nor resulted in any treatment discontinuation. However we observed two respiratory deaths presumably due to infection in nonneutropenic patients with no other predisposing conditions such as pre-existing COPD or lung metastases.
Despite the lack of pharmacokinetic interaction between D and Epi reported by one study [27] , the MTD of the D+Epi combination in our phase I study was shown to be schedule-dependent since the drug administration on consecutive days but not on the same day, even with prophylactic rh-G-CSF, permitted the dose intensification [22] . Toxicity was acceptable and consisted primarily of short-lived grade 3-4 neutropenia with 10% of the cycles complicated by febrile neutropenia. There were no septic deaths. Cardiotoxicity was observed in 9% of patients and was always subclinical. These toxicity data are in agreement with the results of the present study except of the occurrence of the two respiratory deaths which although they were not associated with neutropenia, they may have been related to the immunosuppressive properties of the regimen. Alternatively, they may represent pulmonary toxicity of the combination.
A clear dose-response relationship for single agent epirubicin (up to a dose of 90 mg/m 2 ) has been shown in postmenopausal women with MBC [11] . Furthermore, doubling of the epirubicin dose intensity (100 mg/m 2 versus 50 mg/m 2 ) in the FEC regimen significantly increased the complete and overall response rates but not the overall survival, especially in patients with visceral metastases or multiple metastatic organ sites [12] . To our knowledge, a dose-response relationship has not been demonstrated for docetaxel in the treatment of MBC. However, in two non-randomized studies the administration of docetaxel at 100 mg/m 2 was associated with higher response rate than the 75 mg/m 2 dose [28, 29] , In the present study, prophylactic rh-G-CSF was administered to all patients developing grade 3-4 or febrile neutropenia in order to deliver a high dose intensity for both drugs. This strategy reduced the incidence of severe and febrile neutropenia in subsequent cycles and allowed the administration of the full doses of both drugs for most patients. However, the cost-effectiveness of such an approach has not been demonstrated and therefore may be considered too expensive to use in a palliative setting.
Based on published reports, the D + Epi combination has many theoretical advantages. Both drugs are very active and have a favorable toxicity profile compared to other combinations. In a dose finding study by Pagani et al. [30] , D and Epi were administered on the same day and the MTD was reached at Epi 90 and D 75 mg/m 2 with G-CSF support allowing further dose intensification. Toxicity was primarily grade 3-4 neutropenia with 13% of cycles complicated by febrile neutropenia and one toxic death. There were no clinical signs of cardiotoxicity and among 40 evaluable patients the overall response rate was 60%. In two other phase I-II studies the D + Epi combination has shown high activity and tolerable toxicity without clinical cardiotoxic effects. In the study by Kerbrat et al. [31] , the recommended doses were Epi 100 and D 75 mg/m 2 and they observed 8% complete and 61% partial response rate among 62 evaluable patients. Only 3.2% of the cycles were complicated by febrile neutropenia lasting more than three days. In another phase I-II study by Trudeau et al. [32] , the recommended doses were Epi 60 and D 75 mg/m 2 without G-CSF and Epi 75 and D 75 mg/m 2 with G-CSF support. In the only phase II study of pre-operative chemotherapy with the D+Epi combination, Steger et al. [33] administered D 75 and Epi 75 mg/m 2 together with prophylactic G-CSF to 43 women with primary breast cancer. They observed 22% complete and 62% partial response rate including five patients (16%) with a pathologic complete response.
Taken together the results of the present study as well as the aforementioned reports clearly indicate that the D + Epi combination is very effective and with manageable toxicity and therefore merits further evaluation. Future studies should compare this regimen with other taxaneanthracycline combinations or with 'standard' anthracycline-based therapies.
